Lantheus Holdings, Inc.
Lantheus Holdings, Inc. (NASDAQ: LNTH) is the leading radiopharmaceutical-focused company committed to enabling clinicians to find, fight, and follow disease to deliver better patient outcomes. The company operates through three primary product categories: Radiopharmaceutical Oncology, Precision Diagnostics, and… From the company’s description.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Lantheus Holdings, Inc. does
In the company’s own words
Lantheus Holdings, Inc. (NASDAQ: LNTH) is the leading radiopharmaceutical-focused company committed to enabling clinicians to find, fight, and follow disease to deliver better patient outcomes. The company operates through three primary product categories: Radiopharmaceutical Oncology, Precision Diagnostics, and Strategic Partnerships and Other Revenue.
The Radiopharmaceutical Oncology segment centers on PYLARIFY, an F-18-labeled PET imaging agent targeting prostate-specific membrane antigen approved by the FDA in 2021. PYLARIFY is indicated for PET imaging of PSMA-positive lesions in men with prostate cancer and is manufactured through a diverse network of positron emission tomography manufacturing facilities across the United States, distributed to customers in 48 states plus the District of Columbia and Puerto Rico.
The Precision Diagnostics segment includes DEFINITY, an ultrasound enhancing agent used in echocardiography procedures that holds over 80 percent market share in the U.S. ultrasound enhancing agent segment, and Neuraceq, an F-18-labeled PET imaging agent for Alzheimer's disease diagnostics that the company acquired through its July 2025 acquisition of Life Molecular Imaging Limited. The Strategic Partnerships and Other Revenue segment encompasses biomarker solutions, digital imaging applications including aBSI and aPROMISE, contract development and manufacturing organization services through Evergreen Theragnostics, and royalties from licensed products including flurpiridaz and RELISTOR.
Lantheus maintains a global footprint with headquarters in Massachusetts and offices in New Jersey, Canada, Germany, Switzerland, Sweden, and the United Kingdom. The company serves cardiologists, neurologists, oncologists, radiologists, and other healthcare professionals through hospitals, independent imaging centers, and government facilities throughout the United States and internationally through direct distribution and third-party partnerships.
In 2025, the company executed significant strategic transactions including the acquisition of Life Molecular Imaging Limited and Evergreen Theragnostics, as well as the divestiture of its SPECT business to SHINE Technologies. These transactions reflect the company's strategic focus on growing its commercial portfolio of innovative PET radiodiagnostics and microbubbles while maintaining a robust pipeline of clinical-stage candidates in oncology and neurology.
Company details
- Sector
- Health Care
- Industry (SIC)
- Chemicals
- Headquarters
- BEDFORD, MA
- Fiscal year end
- December
- CIK
- 1521036
- SIC
- 2835
Financial performance, year by year
Fiscal 2015–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Lantheus Holdings, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Lantheus Holdings, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Lantheus Holdings, Inc.’s bonds, as funds hold them
Funds report holding 1 issues of Lantheus Holdings, Inc.’s debt, $169.69M at market value — what funds hold, not the company’s total debt. Weighted-average coupon 2.63%, maturing 2027 to 2027.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Lantheus Holdings, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Lantheus Holdings, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Lantheus Holdings, Inc.'s last four quarterly filings that the numbers alone won't show?”